In search of the Holy Grail in atopic dermatitis: Will dupilumab become the first disease-modifying atopic dermatitis drug? - 03/03/23
Doi : 10.1016/j.jaci.2022.12.824
Thomas Bieber, MD, PhD, MDRA a, b, c, ⁎ 
a Department of Dermatology and Allergy, University Hospital, Bonn, Germany
b Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland
c Davos Biosciences, Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland
∗Corresponding author: Thomas Bieber, MD, PhD, MDRA, Department of Dermatology and Allergy and Christine Kühne-Center for Allergy Research and Education, University Hospital of Bonn, Venusberg Campus 1, D-53127 Bonn, Germany.Department of Dermatology and Allergy and Christine Kühne-Center for Allergy Research and EducationUniversity Hospital of BonnVenusberg Campus 1BonnD-53127Germany
Key words : Atopic dermatitis, dupilumab, disease modification, atopic march
Le texte complet de cet article est disponible en PDF.
| Supported by the Christine Kühne-Center for Allergy Research and Education. |
|
| Disclosure of potential conflict of interest: T. Bieber was a speaker and/or consultant and/or investigator for AbbVie, Affibody, Almirall, AnaptysBio, Arena, Asana Biosciences, ASLAN Pharma, Bayer Health, BioVerSys, Böhringer Ingelheim, Bristol-Myers Squibb, Connect Pharma, Dermavant, DIECE Therapeutics, Domain Therapeutics, EQRx, Galderma, Glenmark, GSK, Incyte, Innovaderm, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, Lòréal, MSD, Novartis, Numab, OM-Pharma, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi/Regeneron, and UCB; in addition, he is founder and chairman of the board of the nonprofit biotech Davos Biosciences. |
© 2023
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 151 - N° 3
P. 694-696 - mars 2023 Retour au numéro
Article précédent
- Knowledge gaps and future opportunities for biologics in childhood allergic and immunologic disorders
- Cullen M. Dutmer, Andrew H. Liu
- Patients with CVID have their own “gut feeling” for viruses
- Raffaele De Palma
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?